to leave a comment.
▲ US Stock Market/AI Generated Image
Global investment bank Morgan Stanley (MS) has identified Alzheimer's treatments, in-vivo gene editing, and AI-based drug development as the three key innovative areas set to revolutionize the future biotech market.
Beincrypto reported on October 1st (local time), citing a report jointly published by Morgan Stanley analysts Sean Laaman and Maxwell Skor, that these three technologies have the potential to offer investors immense profit opportunities. Morgan Stanley particularly estimated the Alzheimer's treatment market size to reach $70 billion. The economic value of Alzheimer's treatment is evaluated to extend beyond mere drug sales, leading to social ripple effects such as significantly reducing nursing facility costs by prolonging the period of independent living for millions of elderly individuals.
In the field of gene editing, in-vivo treatments that directly correct deoxyribonucleic acid (DNA) within the body are rapidly emerging, moving beyond the traditional method of manipulating cells outside the patient's body. Morgan Stanley projected that the in-vivo gene editing market will grow to $10 billion by 2035, even with only initial indications. This is an aggressive figure, exceeding the market consensus of $6 billion by a whopping $4 billion. As early treatments, which focused on liver diseases, expand to areas like the lungs and brain, clinical data to be released over the next 18 months has been identified as a critical turning point that will determine the platform's corporate value.
Artificial intelligence (AI) technology, which innovates the productivity of drug development, was also presented as an attractive investment alternative that can avoid the dichotomous risk of clinical trial success or failure. Unlike traditional biotech ventures whose stock prices fluctuate based on clinical outcomes, software and platform companies that immediately convert technology adoption into revenue are securing stable profit models. Morgan Stanley stated that while it remains cautious about the simple productivity improvement effects for large pharmaceutical companies, it is closely tracking the clinical inflection points of innovative biotech companies built around AI as a core axis.
Even amidst concerns of prolonged high interest rates, the biotech industry is embarking on a new growth cycle, leveraging technological maturity and AI integration. Experts predict that the three technology areas with immense market potential will offset traditional clinical risks and become a key driving force attracting Wall Street capital.
The $70 billion Alzheimer's market and the $10 billion target for gene editing are reshaping the pharmaceutical and biotech industry landscape. Market attention is focused on whether the clinical data pouring out over the next 18 months and the commercialization of AI-based platforms can lead to a major uptrend in the biotech sector.
[Article Key Summary]
-Morgan Stanley (MS) selected Alzheimer's treatments, in-vivo gene editing, and AI for drug development as the three key innovation themes.
-The in-vivo gene editing market size is projected to reach $10 billion by 2035, exceeding market consensus by $4 billion.
-The $70 billion Alzheimer's market and the commercialization of AI platforms are analyzed to determine investment value over the next 18 months.
*Disclaimer: This article is for investment reference only, and we are not responsible for any investment losses based on it. The content should be interpreted for informational purposes only.*
Newsletter
Get key news delivered to your email every morning
to leave a comment.